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Abstract
Background: We introduce a promising methodology to identify new therapeutic targets in cancer. Proteins bind to
nanoparticles to form a protein corona. We modulate this corona by using surface-engineered nanoparticles, and identify
protein composition to provide insight into disease development.
Methods/Principal Findings: Using a family of structurally homologous nanoparticles we have investigated the changes in
the protein corona around surface-functionalized gold nanoparticles (AuNPs) from normal and malignant ovarian cell
lysates. Proteomics analysis using mass spectrometry identified hepatoma-derived growth factor (HDGF) that is found
exclusively on positively charged AuNPs (
+AuNPs) after incubation with the lysates. We confirmed expression of HDGF in
various ovarian cancer cells and validated binding selectivity to
+AuNPs by Western blot analysis. Silencing of HDGF by
siRNA resulted s inhibition in proliferation of ovarian cancer cells.
Conclusion: We investigated the modulation of protein corona around surface-functionalized gold nanoparticles as a
promising approach to identify new therapeutic targets. The potential of our method for identifying therapeutic targets was
demonstrated through silencing of HDGF by siRNA, which inhibited proliferation of ovarian cancer cells. This integrated
proteomics, bioinformatics, and nanotechnology strategy demonstrates that protein corona identification can be used to
discover novel therapeutic targets in cancer.
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Introduction
Gold nanoparticles (AuNPs) have been widely studied for their
potential in disease therapeutics as targeting agents, drug delivery
vehicles, and as therapeutic agents themselves [1,2]. When
nanoparticles are exposed to biological fluids via systemic
administration or ex vivo incubation, they interact with proteins
to form a biological coating on the AuNP to form a protein coating
or corona. This corona dictates the biological response, as well as
many physical properties, of the AuNP [3]. Identifying the
contents of the protein corona can provide unique insight into the
biological function of the AuNPs, including their biodistribution,
clearance, and potential toxicity [4,5],[6–9]. In addition to
affecting nanoparticle behavior, the process of corona formation
provides a tool for probing the local proteome [10]. As such,
protein-covered nanoparticles may also provide insight into
disease states and thereby help to identify new therapeutic targets.
Formation of the protein corona will depend on the nature of
the interaction between the nanoparticles/conjugates and the
biological fluids chosen [11], as dictated by the surface properties
of the nanoparticles [12]. The nature of the interaction will
depend mainly on i) the charge of the nanoconjugate, i.e., positive,
negative, zwitterionic, or neutral and ii) the hydrophobicity/
hydrophilicity of the conjugate. In this manuscript, we examine
the nature of the protein corona captured by surface-functiona-
lized AuNPs when exposed to clinically relevant biological fluids,
and reveal that tuning the nanoparticle surface charge can
preferentially enrich and therefore enable detection of otherwise
undetected low-abundance proteins as possible therapeutic targets.
We used a combination of UV-Visible spectroscopy (UV-Vis),
dynamic light scattering (DLS), zeta potential measurement, and
Bradford protein assay to characterize the protein corona.
Proteomics/bioinformatics analysis was used to identify low-
abundance proteins only found when enriched on the nanoparticle
surface. We incubated AuNPs with normal and malignant ovarian
cell lysates using positively and negatively charged AuNPs
(
+AuNPs and
2AuNPs, respectively). In this study, we established
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33650HDGF as a possible therapeutic target for ovarian cancer by use of
proteomic analysis and expression levels in cancer cells. This
approach was validated through inhibition of cell proliferation
upon silencing this factor by siRNA. Taken together, we show that
this technique can be used to identify and validate new therapeutic
targets for ovarian cancer, providing a generalized strategy for
potential use in other diseases.
Results
Characterization of protein corona around surface-
modified AuNPs from the lysates of normal OSE (Ovarian
Surface Epithelial) and malignant serous ovarian cells
(OV167)
Lysates were collected from ovarian cell lines, OV167
(malignant) [13] and OSE (non-cancerous) [14] were incubated
with
+AuNPs and
2AuNPs to form protein coronas. By subtracting
the amount of protein in the supernatants from the amount of
protein in the non-gold control (equal to the molar amount of
lysate in the buffer solution) the amount of protein adsorbed onto
the AuNP surface was determined (Figure 1A). In these studies,
137 mg protein from the OV 167 cell lysate per 50 mL
nanoparticle adsorbed onto the
2AuNP surface as opposed to
106 mg from the OSE lysate nanoparticle (Figure 1B). Similar
amounts of protein also adsorbed onto
+AuNP (124 mg and 97 mg
from OV 167 and OSE lysates, respectively). The size of the
particles was examined by DLS before and after incubation with
cell lysates (Figure 1C and 1D). The hydrodynamic diameter (dH)
of
+AuNP, increased from 10 nm (Z-average) for the two
nanoparticles prior to incubation(
+AuNP and
2AuNP) with a
Gaussian distribution (Table 1) to 32 and 24 nm after incubation
with OV167 and OSE lysates, respectively (Figure 1C). For
2AuNP, dH increased from 10 nm to 28 and 43 nm after
incubation with OV167 and OSE lysates, respectively (Figure 1D).
Upon formation of the protein corona, the zeta potential of
2AuNPs decreased from 244 mV to 225 mV (OV167) and
230 mV (OSE), respectively. Similarly, incubation with OV167
and OSE lysates decreased the zeta potential of
+AuNP from
+25 mV to +5 mV and 23 mV, respectively (see Table 2). These
data indicate that
+AuNPs and
2AuNPs both form different
protein coronas from malignant and normal cell lysates and both
lead to increased hydrodynamic diameter and a change in overall
charge.
Validating reproducibility of corona formation around
surface-modified AuNPs
The protein coronas formed with
+AuNP and
2AuNP
nanoparticles and the OV167 and OSE lysates were analyzed
and identified by means of mass spectrometry. The relationship of
the proteins identified from the lysate-formed coronas of
+AuNP
Figure 1. Characterization of the AuNP and protein corona made from cell lysates of OSE and OV167. a) A cartoon showing
functionalization of 5 nm gold nanoparticle to create positively charged (
+AuNP) or negatively charged (
2AuNP) gold nanoparticles. b) Amount of
protein bound on the nanoparticle as determined by Bradford assay. The binding of protein is evident from the increase in surface size via DLS on c)
+AuNP and d)
2AuNP.
doi:10.1371/journal.pone.0033650.g001
Protein Corona and Cancer
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33650and
2AuNP is shown in Figure 2 (see also Figure S1, Figure S2,
Figure S3 and Tables S1, S2, S3, S4, S5, S6, S7, S8, S9, S10).
Bioinformatics analysis of the proteins identified by proteomics
studies from OSE lysates revealed a number of proteins that were
uniquely found in the coronas of
2AuNP (47) and
+AuNP (33),
(Figure 2A and Table S1). Similar analysis of the corona proteins
from OV167 lysates showed that unique proteins were in the
formed coronas of
+AuNPs (18) and
2AuNPs (72), respectively
(Figure 2B and Table S2). It is important to note that the unique
proteins are exclusive to
+AuNP and
2AuNP and not found at
detectable levels in the corresponding cell lysates. These data
clearly demonstrate the concentrating effect of protein corona
formation upon low-abundance proteins. The identification of all
the proteins is provided in the Supplementary material (see Tables
S1, S2, S3, S4, S5, S6, S7, S8, S9, S10).
Identification of new molecular targets from the protein
corona formed on surface-modified AuNPs
We next compared the selectivity of each nanoparticle in
discerning different proteins from OSE and OV167 cell lysates,
as shown in Figure 3. A closer examination of our results showed
that there was neither a distinct functional class nor a particular
range of pIs in which the proteins bound to the nanoparticles
(data not shown), which is consistent with prior findings [15].
Based on the selectivity, we investigated whether modulation of
protein-corona formation by surface-functionalized nanoparticles
could be applied to discover new therapeutic targets for cancer.
Proteomics/bioinformatics analysis revealed hepatoma-derived
growth factor (HDGF) to be a component of the
+AuNP protein
corona from the malignant OV167 cells; thus, this was selected as
a possible target. HDGF has recently been implicated in the
pathogenesis of several other cancers but its role in ovarian
cancer remains unknown so far. To further validate the specificity
of
+AuNP and
2AuNP towards preferential enrichment of low
abundance proteins, we selected Hsp70, Hsp90 and HDGF. As
mentioned earlier HDGF and Hsp90 were only present in
+AuNP and
2AuNP corona of OV167 proteome, respectively.
Hsp70 was used as a control due to its commonality between
OSE and OV 167 lysates as well as to the protein corona formed
on both
+AuNP and
2AuNP. Western blot analysis shows that
HDGF is indeed preferentially enriched on the
+AuNPs, whereas
it is not detected either in the lysates or on
2AuNPs, confirming
the results from tandem MS. Similarly, Hsp90 is preferentially
detected on
2AuNPs, whereas Hsp70 is detected in all the
fractions (Figure 4A).
We then investigated the functional consequences of the
presence of HDGF in ovarian cancer. We first determined the
expression levels of HDGF in various ovarian cancer cell lines. As
seen in the Western blot, HDGF is expressed across various
ovarian cancer cell lines, with the highest expression in A2780 cell
line [16] and the lowest in normal OSE (Figure 4B). To
demonstrate functional effects we knocked down HDGF in
A2780 cells, by using siRNA (KD-siRNA) and looked at the
proliferation of the ovarian cancer cells. We chose A2780 cells
because they expressed the highest level of HDGF of the cells
tested. The silencing of HDGF was confirmed by Western blot
analysis, and there was a convincing level of significant knockdown
as compared to the scrambled control (Figure 4C). In addition,
silencing of HDGF results in significant inhibition of proliferation
of ovarian cancer cells (,70%) as compared to the scrambled
siRNA (sc-siRNA) control (Figure 4D). These results verify that
HDGF is a potential therapeutic target in ovarian cancer.
Discussion
Ovarian cancer is the most common malignancy of the female
genital tract and one of the most lethal [17],[18], essentially
because there are currently no early screening or diagnostic tests
for this disease. As a result, the cancer often remains clinically
undetected until the later stages of the disease [19]. Even though
patients respond initially to chemotherapy after surgical debulking,
most of them develop terminal drug-resistant relapse [20]. Hence,
new therapeutic strategies, and thus new targets, are urgently
needed to combat ovarian cancer. Identifying constituents of the
protein corona that is formed when metal nanoparticles are
incubated with cell lysates by using a combination of proteomics,
bioinformatics, and nanotechnology could provide useful infor-
mation regarding the development of the disease and allow us to
discover new therapeutic targets in ovarian cancer, as well as
potentially for other cancers in the future.
Quantitative proteomics has allowed researchers to study
protein populations found in tissues or biofluids [21] [22] [23].
One technique used to study these protein sets is mass
spectrometry, a detection tool with the ability to screen for myriad
of proteins [24]. In general, mass spectrometry-based proteomics is
used to interpret the information encoded from genomes [25].
Protein analysis by mass spectrometry has been fairly reliable
when applied to small sets of protein samples [26] [27]. However,
low-abundance proteins may escape detection using these general
methodologies due to the Vroman effect, in which highly mobile
proteins that adsorb onto surfaces are replaced by less mobile
proteins [28],[29,30]. In the present study, we were able to
differentially detect proteins not observed in the cell lysates using
conventional methods. In our strategy, these low abundance
proteins were enriched by selective interaction with the modified
surface of gold nanoparticles. The different proteins that adsorb
onto the surface of the nanoparticle are reflected in protein corona
light-scattering behavior, charge, and proteomics. These results
clearly suggest that tuning the surface charge of engineered
nanoparticles can modulate the formation of protein corona
around them. Such modulation is important to detect low-
abundance proteins in order to identify new therapeutic targets.
Table 1. Dynamic Light Scattering (DLS) to determine
hydrodynamic diameter (dH) of AuNPs before and after
incubation with OV167 and OSE lysates.
+AuNP (dH)
2AuNP (dH)
Particle only 10 nm 10 nm
OV167 32 23 nm
OSE 24 43 nm
doi:10.1371/journal.pone.0033650.t001
Table 2. Zeta Potential in mV of
+AuNP and
2AuNP before
and after incubation with the lysates of OV167 and OSE,
respectively.
+AuNP
2AuNP
Particle only +2565 245610
OV167 +563 22568
OSE 2362 230611
doi:10.1371/journal.pone.0033650.t002
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the interactions between proteins and nanoparticles in various bio-
fluids and their biophysical properties with respect to drug delivery
and therapeutics. To this end, research groups have intently
focused on determining the composition of the nanoparticle
corona with human plasma [3,7,12,15,31,32], demonstrating that
nanoparticle surface size and properties play a critical role in
protein adsorption [33–35]. Subsequent work also suggests that
the protein corona is important for how the cell perceives and
transports the nanoparticles [36]. In parallel to gaining knowledge
in the selective affinity of nanoparticles for proteins, research has
also focused on coating the surface of nanoparticles to detect
specific antigens and protein sequences [34,37–39]. The study
presented here uses nanoparticles as useful tools for enrichment
and detection of low abundance proteins as a unique approach to
discover new therapeutic targets. Using bioinformatics, we were
able to further distinguish proteins that are uniquely adsorbed to
either
+AuNPs or
2AuNPs; these were validated via Western blot
analysis. One of the proteins we chose to examine more closely is
HDGF, which was identified as a possible ovarian-cancer-specific
mitogen because it was found only with the lysates of the
malignant cells, and only on the
+AuNPs. To date, it has not been
established if HDGF has a role in ovarian cancer. However, it has
been implicated in other cancers, such as melanoma, pancreatic,
and lung [40–42]. From our studies, we showed that in
comparison to OSE, HDGF is greatly over expressed in OV
167 and A2780 cell lines. Upon knockdown of HDGF expression,
we observed that the proliferation of ovarian cancer cells was
vastly reduced. These results correlate strongly with previous
studies which showed that HDGF is co-expressed with prolifer-
ating cell nuclear antigen (PCNA) in smooth muscle cells [43].
These results demonstrate, for the first time, a possible role of
HDGF in ovarian cancer pathogenesis and present it as a potential
therapeutic target. They also introduce a new methodology of
exploiting nanoparticle corona content to identify potential
therapeutics.
In summary, this paper employs a unique combination of tools:
proteomics, bioinformatics, and nanotechnology, to open up a
new avenue for identifying and validating new therapeutic targets
in cancer. Using surface-modified gold nanoparticles, we success-
fully enriched low-abundance proteins from lysates of normal and
malignant ovarian cancer cells and identified them using a
combination of proteomics and bioinformatics analysis. Although
we focused on HDGF in this study, extension of similar methods to
other protein targets to target other diseases would be valid. Future
studies will focus on the evolution, modulation, and identification
of protein coronas over time and also on testing this unique system
with human patient samples (blood, serum, plasma). This study
Figure 2. Selectivity of the proteins bound to positively charged (
+AuNP) vs negatively charged (
2AuNP) particles. Venn diagrams
show proteins identified in the protein corona around
+AuNP and
2AuNP from a) normal OSE cell lysates and b) malignant OV167 cell lysates. The
figure clearly depicts the preferential enrichment of low abundance proteins by engineered nanoparticles that were not detectable in the lysates by
proteomics analysis. These proteins, which were otherwise undetected, could potentially be new therapeutic targets.
doi:10.1371/journal.pone.0033650.g002
Figure 3. Venn diagram demonstrating the difference between
the proteins that make up the corona for a)
+AuNP, b)
2AuNP
from the cell lysates and c) the different between proteins in
the OV167 and OSE cell lysates. These differences in the
composition of the lysates could be exploited to identify new
therapeutic targets in ovarian cancer.
doi:10.1371/journal.pone.0033650.g003
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networks, not only for cancer but also for other diseases, by
detecting low-abundance undetectable proteins using enrichment
induced by surface-engineered nanoparticles.
Materials and Methods
Gold salt was purchased from Strem Chemicals (Newburyport,
MA). PBS,RPMI and DMEM was purchased from Mediatech,
(Manassas, VA). HDGF antibody was purchased from Santa Cruz
Biotechnologies (Santa Cruz, CA) and tubulin was purchased from
AbCam (Cambridge, MA). Secondary antibodies were purchased
from Santa Cruz. Antibodies to HSP70 and HSP90 were a gift
from Dr. Scott Kaufmann.
Particle synthesis
Gold nanoparticles were synthesized according to methods
reported by You et al [44]. In brief, AuNPs were synthesized via
the one-pot protocol developed by Schiffrin et al [45]. Further
functionalization was performed using the Murray place-exchange
method [46], with our thiolated ligands bearing an amine or
carboxylate end group [47].
Cell Lysates
Cells were grown using standard conditions. A2780 cells were
grown using RPMI media with 10% FBS and 1% antibiotic/
antimycotic. OSEcellsgrown in were medium 199withEarle’s salts
(Sigma, St. Louis, USA) and MCDB 202 (Sigma), 1:1 ratio, with
15% Fetal Bovine Serum (FBS). OV167, OVCAR5, and SKOV
IP3 were grown in DMEM (10% FBS and 1% antibiotic/
antimycotic). For each cell line, 26150 mm dishes were grown to
confluence (,90%). Prior to lysing, the plates were rinsed five times
with 16phosphate-buffered saline (PBS) buffer to help reduce the
amount of fetal bovine serum. Cells were then lysed using Ripa
buffer (1 mL) with protein inhibitor cocktail (10 mL added) on ice
for 30 minutes. The lysates were scraped off the plate and collected
into a mini-centrifuge tube. The tubes were centrifuged at
14,000 rpm for 12 minutes at 4uC (twice) and the supernatants
were collected. Cell lysates were kept at 220uC until needed.
Corona Formation
Gold nanoparticles (1.2 mM) were incubated for 1 hour with
0.2 mg/mL of cell lysates at room temperature. The lysate/
nanoparticle mixture was subjected to centrifugation (100,0006g/
45 min/10uC) and the supernatant collected. The nanoparticle-
corona pellet was washed with 1 mL of water and resuspended
and re-centrifuged (100,0006 g/45 min/10uC) and the resulting
supernatant and pellets collected. The supernatants were mea-
sured for protein content via Bradford assay. The pellets were
further analyzed for protein identification using MS-MS.
DLS and Zeta Potential Analysis
A Malvern Zetasizer Nano ZS instrument was used to measure
zeta potential at 25uC for all nanoparticles. Samples were
prepared as mentioned above. Samples were loaded into a pre-
rinsed folded capillary cell for the zeta potential and DLS
measurements. The principle employed was ELS (Smoluchowski
methodology for aqueous media) in a Zetasizer Nano ZS
instrument. A maximum of 100 sub runs was performed until a
constant value was obtained.
Western Blot Analysis
Nanoparticle-protein corona was centrifuged as described
above. The supernatant was separated from the pellet. The pellet
Figure 4. Enrichment and functional consequence of HDGF. a) Western blot confirming the presence of HDGF on
+AuNP- corona whereas
Hsp90 on
2AuNP- corona. Also shown is Hsp70 (known to be present in all NP coronas via MS). b) Expression of HDGF in ovarian cell lines. c)
Knockdown of HDGF in A2780 cell line using HDGF-siRNAs (KD-siRNA) and compared with the scrambled control (scRNA); d) Effect of silencing HDGF
on proliferation of ovarian cancer cells analyzed by [3H]-thymidine incorporation assay.
doi:10.1371/journal.pone.0033650.g004
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Laemmeli’s solution and 2.5% 2-bmercaptoethanol. The mixture
was boiled at 95uC for 15 minutes and centrifuged at 4uCa t
16500 rpm for 15 minutes. The supernatant is separated from the
resulting pellet and 30 ml loaded on to gels. As for the control,
30 ml of the cell lysate was aliquoted from 200 mg/mL of lysate
solution and boiled with 25% Laemmeli’s solution at 95uC for
5 minutes. The proteins were run on a 10% gel and transferred to
a PVDF membrane at 100V for 40 minutes. The membrane was
blocked with 4% milk and incubated with primary antibodies
overnight.
siRNA Knockdown
A2780 cells were plated in 60-mm dishes with 3 mL cell culture
media. Cells were transfected with 20 mLo f2 0 mM siRNA
purchased from Qiagen (Valencia, CA) along with 20 mLo f
HiPerfect (Valencia, CA) and 500 mL of OPTI-MEM (Invitrogen,
Carlsbad, CA). Scrambled siRNA from Qiagen was used as a
control. After 48 hours, cells were counted and plated on 24-well
plates (3610
4 cells/mL) containing 1 mL media. Cell lysate was
also collected for Western blot analysis. 20 mg of whole-cell lysates
were used to detect the knockdown efficiency of the siRNA.
3H-Thymidine incorporation assay for cellular
proliferation
Cells transfected with siRNA were seeded (2610
4) in 24-well
plates. After overnight incubation under standard conditions,
1 mCi/ml [3H]-thymidine was added to fresh media, and 4 h
later, cells were washed with ice-cold PBS, fixed with 100% cold
methanol followed by washing and lysing with 250 ml 0.1N
NaOH. [3H]-thymidine incorporation in the cells was measured
in a scintillation counter.
Mass Spectrometry; Protein identification via trypsin
digest R nanoLC-MS/MS with hybrid orbitrap/linear ion
trap mass spectrometry
The nanoparticle solutions were prepared for mass spectrom-
etry analysis using the following procedures. The solutions were
dried on a SpeedVac spinning concentrator (Savant Instruments,
Holbrook NY), then solubilized in 50 mM Tris/0.25% Protease
Max (Promega Corporation, Madison, WI). The proteins were
reduced and alkylated with tris(2-carboxyethyl)phosphine (TCEP)
at 55uC for 40 minutes and iodoacetamide at room temperature
for 40 min in the dark, then digested with trypsin (Promega
Corporation, Madison WI) in 50 mM Tris pH 8.1/0.0002%
Zwittergent 3–16, at 37uC overnight. The digest was terminated
with 2% trifluoroacetic acid, and acetonitrile was added, then
centrifuged to pellet the particles. The supernatant was removed
and concentrated to less than 5 mL on a SpeedVac spinning
concentrator (Savant Intruments, Holbrook NY). The digest
mixture was brought up in 0.2% trifluoroacetic acid for protein
identification by nano-flow liquid chromatography electrospray
tandem mass spectrometry (nanoLC-ESI-MS/MS) using a
ThermoFinnigan LTQ Orbitrap Hybrid Mass Spectrometer
(Thermo Fisher Scientific, Bremen, Germany) coupled to an
Eksigent nanoLC-2D HPLC system (Eksigent, Dublin, CA). The
peptide digest mixture was loaded onto a 250 nL OPTI-PAK trap
(Optimize Technologies, Oregon City, OR) custom-packed with
Michrom Magic C8 solid phase (Michrom Bioresources, Auburn,
CA). Chromatography was performed using 0.2% formic acid in
both the A solvent (98% water/2% acetonitrile) and B solvent
(80% acetonitrile/10% isopropanol/10% water), and a 5%B to
40%B gradient over 100 minutes at 325 nL/min through a hand-
packed PicoFrit (New Objective, Woburn, MA) 75 mm6200 mm
column (Michrom Magic C18, 3 mm). The LTQ Orbitrap mass
spectrometer experiment was set to perform a Fourier-transformed
full scan from 375–1600 m/z with resolution set at 60,000 (at
400 m/z), followed by linear ion trap MS/MS scans on the five
most abundant ions. Dynamic exclusion was set to 1 and selected
ions were placed on an exclusion list for 30 seconds. The lock-
mass option was enabled for the FT full scans using the ambient
air polydimethylcyclosiloxane (PCM) ion of m/z=445.120024 or
a common phthalate ion m/z=391.284286 for real-time internal
calibration [48].
Mass Spectrometry; Protein and Peptide Identification
Tandem mass spectra were extracted by using BioWorks version
3.2. All MS/MS samples were analyzed using Mascot (Matrix
Science, London, UK; version 2.2.04), Sequest (ThermoFinnigan,
San Jose, CA; version 27, rev. 12) and X! Tandem (www.thegpm.
org; version 2006.09.15.3). All the three applications identify
peptides by comparing the experimental spectra to predicted
spectra of peptide derived from the protein sequence available in
the Swissprot database (699052 entries), assuming trypsin
digestion. For the three applications the fragment ion mass
tolerance was set to 0.80 Da. Parent ion tolerance was respectively
set to 10.0 PPM for Mascot and X! Tandem and 0.0084 Da for
Sequest. Oxidation of methionine and iodoacetamide derivative of
cysteine were specified as variable modifications in Mascot,
Sequest and X! Tandem. The applications returned the list of
identified peptides, associated proteins, and confidence score.
Scaffold (version Scaffold_2_00_06, Proteome Software Inc.,
Portland, OR) was used to combine the output of Mascot,
X!Tandem and Sequest to enhance protein identifications.
Confidence scores were combined in a probability model as
specified in the PeptideProphet algorithm [49]; this model was
used to score each peptide. Peptides with a probability score lower
than 95.0% were rejected from the analysis. Proteins were then
scored by an algorithm included in PeptideProphet [50] that also
used a statistical model. Proteins that were associated with the
same set of peptides and therefore could not be further
discriminated were jointly associated to these peptides.
Bioinformatics
The Mascot output is further processed by a set of bioinfor-
matics procedures. Output files are summarized at the protein
level to include one protein per entry. Since peptides can be
related to several member of a protein family, only proteins with
the extension ‘_HUMAN’ were retained during the processing;
those not related to human proteins were rejected. The sequence
of each protein was extracted from the Uniprot database (http://
www.uniprot.org/ version May 15,2011). Protein comparison was
performed based on the sequence of each protein rather than its
name.
Supporting Information
Figure S1 A combination of MS and bioinformatics
tools was used to identify proteins bound to the AuNPs
surface from the OSE lysate. Venn diagram shows the
reproducibility of the identification process with triplicate MS runs
for proteins associated with the different AuNPs.
(TIF)
Figure S2 A combination of MS and bioinformatics
tools was used to identify proteins bound to the AuNPs
surface from the OV167 lysate. Venn diagram shows the
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for proteins associated with the different AuNPs.
(TIF)
Figure S3 Characterization of the AuNP and protein
corona made from cell lysates of a) normal ovarian cell
line (OSE) and b) ovarian cancer cell line (OV167). The
binding of protein is evident from the increase in UV absorbance.
(TIF)
Table S1 Unique Proteins present in the corona of
+AuNP and
2AuNP from OSE lysate.
(DOCX)
Table S2 Unique proteins present in the corona of
+AuNP and
2AuNP from OV167 lysate.
(DOCX)
Table S3 All Proteins OSE Lysate.
(DOCX)
Table S4 All proteins present in the corona of
+AuNP
from OSE lysates.
(DOCX)
Table S5 All proteins present in the corona of
2AuNP
from OSE lysates.
(DOCX)
Table S6 All proteins present in OV167 lysate.
(DOCX)
Table S7 All proteins in the OV167
+AuNP corona.
(DOCX)
Table S8 All proteins in the OV167
2AuNP corona.
(DOCX)
Table S9 Comparison of proteins present in
2AuNP
corona from OSE and OV167 lysates.
(DOCX)
Table S10 Comparison of proteins present in
+AuNP
corona from OSE and OV167 lysates.
(DOCX)
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